Saverna Therapeutics AG

Saverna Therapeutics AG is a Swiss pharmaceutical start-up company founded in November 2017 in the Basel area to create the most innovative and advanced platform targeting non-coding RNA (ncRNA). The aim is to develop new small molecule medicines to treat diseases with an unmet medical need. We focus on the disease areas inflammation, cancer and infection.
The strategy of Saverna is to identify low molecular weight, cell-permeable, orally available compounds targeting the ncRNA and to develop these into drugs to treat diseases with unmet medical need.
Saverna Therapeutics AG has integrated the latest advances in Nuclear Magnetic Resonance for drug discovery, in-silico machine learning and fragment-based screening to generate new chemical entity targeting ncRNA.